Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion

Table 3 Immune checkpoint inhibitors as an adjuvant therapy for hepatocellular carcinoma patients with microvascular invasion

NCT number	Title	Interventions	Characteristics	n	Date	Current status
NCT04682210	Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection	Drug: Sintilimab. Drug: Bevacizumab	Phase: 3. Allocation: Randomized. Intervention model: Parallel	246	December, 2020 to December, 2024	Not yet recruiting
NCT04981665	A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection	Drug: Tislelizumab. Drug: TACE	Phase: 2. Allocation: N/A. Intervention model: Single group assignment	50	November 8, 2021 to December, 2024	Recruiting
NCT05407519	A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection	Drug: Tislelizumab. Drug: Sitravatinib	Phase: 2. Allocation: N/A. Intervention model: Single group assignment	52	July 25, 2022 to June 30, 2026	Recruiting
NCT04639180	A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation	Drug: Camrelizumab.Drug: Rivoceranib (apatinib)	Phase: 3. Allocation: Randomized. Intervention model: Crossover assignment	674	April 1, 2021 to July 31, 2024	Recruiting
NCT03839550	Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection	Drug: Apatinib Mesylate. Drug: SHR-1210	Phase: 2. Allocation: Randomized. Intervention model: Parallel	200	February 15, 2019 to February 28, 2023	Not yet recruiting
NCT03847428	Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2)	Drug: Durvalumab. Drug: Bevacizumab. Other: Placebo	Phase: 3. Allocation: Randomized. Intervention model: Parallel	908	April 29, 2019 to May 31, 2024	Not yet recruiting
NCT04102098	A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050)	Drug: Atezolizumab. Drug: Bevacizumab	Phase: 3. Allocation: Randomized. Intervention model: Parallel	668	December 31, 2019 to July 16, 2027	Not yet recruiting

TACE: Transcatheter arterial chemoembolization; HCC: Hepatocellular carcinoma.